TRIPLE-S MANAGEMENT CORP

Form 4

October 14, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. See Instruction

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **ACCIPITER CAPITAL** Issuer Symbol MANAGEMENT, LLC TRIPLE-S MANAGEMENT CORP (Check all applicable) [GTS] _X__ 10% Owner (Last) (First) (Middle) 3. Date of Earliest Transaction Director _ Other (specify Officer (give title (Month/Day/Year) below) 666 5TH AVENUE, 35TH FLOOR 10/09/2008 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting NEW YORK, NY 10103 Person

						•	C13011		
(City)	(State)	(Zip) Tal	ble I - Non-	-Derivativo	e Secu	rities Acqui	red, Disposed of	, or Beneficia	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securiti nor Dispose (Instr. 3, 4)	ed of (` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class B Common Stock, par value \$1.00 per share	10/10/2008		P		` ,	\$ 11.6269	473,163	I	By ALSF II, LP (1)
Class B Common Stock, par value \$1.00 per share	10/09/2008		P	11,800	A	\$ 12.345 (2)	11,800	I	By Gabe Hoffman

Class B Common Stock, par value \$1.00 per share	10/09/2008	P	23,200	A	\$ 12.9013 (3)	35,000	I	By Gabe Hoffman
Class B Common Stock, par value \$1.00 per share						463,454	I	By ALSF (Offshore), Ltd. (4)
Class B Common Stock, par value \$1.00 per share						914,062	I	By ALSF II (Offshore), Ltd. (5)
Class B Common Stock, par value \$1.00 per share						529,079	I	By ALSF II (QP), LP (6)
Class B Common Stock, par value \$1.00 per share						462,741	I	By ALSF, LP (7)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exercisable and	7. Title and	8. Price of	ç
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onNumber	Expiration Date	Amount of	Derivative	J
Security	or Exercise		any	Code	of	(Month/Day/Year)	Underlying	Security	,
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e	Securities	(Instr. 5)]
	Derivative				Securities		(Instr. 3 and 4)		(
	Security				Acquired]
					(A) or				J
					Disposed				-
					of (D)				(
					(Instr. 3,				

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

4, and 5)

				Amount
Code V (A) (D)	Date Exercisable	Expiration Date	Title	or Number of Shares
Code (11) (D)				Dilaics

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
ACCIPITER CAPITAL MANAGEMENT, LLC 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				
ACCIPITER LIFE SCIENCES FUND II L P 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				
Accipiter Life Sciences Fund II Offshore Ltd 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				
ACCIPITER LIFE SCIENCES FUND II QP L P 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				
ACCIPITER LIFE SCIENCES FUND LP 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				
ACCIPITER LIFE SCIENCES FUND OFFSHORE LTD 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				
Candens Capital LLC 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				
HOFFMAN GABE 666 5TH AVENUE, 35TH FLOOR NEW YORK, NY 10103		X				

Signatures

By: Accipiter Capital Management, LLC; By: /s/ Gabe Hoffman, Managing Member	10/14/2008
**Signature of Reporting Person	Date
By: Accipiter Life Sciences Fund II, LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member	10/14/2008
**Signature of Reporting Person	Date
By: Accipiter Life Sciences Fund II (Offshore), Ltd.; By: Accipiter Capital Management, LLC, its Investment Manager; By: /s/ Gabe Hoffman, Managing Member	10/14/2008

Reporting Owners 3

**Signature of Reporting Person	Date
By: Accipiter Life Sciences Fund II (QP), LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member	10/14/2008
**Signature of Reporting Person	Date
By: Accipiter Life Sciences Fund, LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member	10/14/2008
**Signature of Reporting Person	Date
By: Accipiter Life Sciences Fund (Offshore), Ltd.; By: Accipiter Capital Management, LLC, its Investment Manager, By: /s/ Gabe Hoffman, Managing Member	10/14/2008
**Signature of Reporting Person	Date
By: Candens Capital, LLC; By: /s/ Gabe Hoffman, Managing Member	10/14/2008
**Signature of Reporting Person	Date
By: /s/ Gabe Hoffman	10/14/2008

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**Signature of Reporting Person

Held by Accipiter Life Sciences Fund II, LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund II, LP and Gabe (1) Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

Date

- The range of prices for the transactions reported in this line was \$11.62 to \$12.51. The Reporting Person undertakes to provide full (2) information regarding the number of shares purchased at each separate price upon request by the Commission, the issuer or a security holder of the issuer
- The range of prices for the transactions reported in this line was \$12.64 to \$13.05. The Reporting Person undertakes to provide full (3) information regarding the number of shares purchased at each separate price upon request by the Commission, the issuer or a security holder of the issuer.
- Held by Accipiter Life Sciences Fund (Offshore), Ltd. Accipiter Capital Management, LLC, the investment manager of Accipiter Life
 (4) Sciences Fund (Offshore), Ltd. and Gabe Hoffman, the managing member of Accipiter Capital Management, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.
- Held by Accipiter Life Sciences Fund II (Offshore), Ltd. Accipiter Capital Management, LLC, the investment manager of Accipiter Life (5) Sciences Fund II (Offshore), Ltd. and Gabe Hoffman, the managing member of Accipiter Capital Management, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.
- Held by Accipiter Life Sciences Fund II (QP), LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund II (QP), LP (6) and Gabe Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.
- Held by Accipiter Life Sciences Fund, LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund, LP and Gabe (7) Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4